Biogen's lecanemab shows less cognitive decline with Alzheimer's, but more brain swelling

Nov. 29, 2022 8:58 PM ETEisai Co., Ltd. (ESALF), ESALY, BIIBBy: Jonathan Block, SA News Editor5 Comments

Amyloid plaques in Alzheimer"s disease

Artur Plawgo

Fresh data on Biogen (NASDAQ:BIIB) and Eisai's (OTCPK:ESALY) (OTCPK:ESALF) experimental Alzheimer's treatment lecanemab indicated that while the biologic led to moderately less decline in cognition and function compared to placebo, it was also

Recommended For You

Comments (5)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.